Tariffs and Aesthetic Injectables:

IMPACT REPORT

April 2025

Tariffs and Aesthetic Injectables: Impact Analysis

April 2025

Introduction

The resurgence of Donald Trump's aggressive trade policies has put new tariffs at the center of U.S. economic strategy. In his 2024 campaign and early 2025 presidency, Trump proposed sweeping import tariffs – including a universal duty on all imports and steeper levies on specific countries – as leverage to rebalance trade. Traditionally, pharmaceutical products *(including aesthetic injectables like Botox)* were spared in trade wars due to patient welfare concerns. However, recent statements and measures suggest these **exemptions may be ending**, raising questions about how **Botox and similar aesthetic treatments** will be affected. This report examines the latest tariffs (proposed and enacted), their scope, and how they could influence the **pricing, availability, and supply chain** of popular cosmetic injectables. We also provide strategic recommendations for medical spa (medspa) owners to navigate these changes.

Trump's Proposed and Enacted Tariffs (2024–2025)

Trump's trade agenda has centered on broad tariffs applied in phases, alongside targeted measures against trading partners with large deficits or specific policy disputes. **Table 1** summarizes key tariff proposals and actions from the 2024 campaign into 2025:

- Universal or "Reciprocal" Tariffs on *All* Imports
- Country-specific tariffs (notably on **China**, **Mexico**, **Canada**, and threatened on **Europe**)
- Industry-specific tariffs, including the **pharmaceutical sector** (breaking with past precedent of excluding medicines)

Table 1. Major Tariff Proposals/ACTIONS Under Trump (2024–2025)

Tariff Plan	Scope / Targets	Proposed Rate	Status (Early 2025)
"Universal" Import Tariff (Campaign pledge)	*All* imports to the U.S. (global)	*10%*, with hints up to 20%	**In development:** Economic team drafting "reciprocal tariffs" on every country. Not yet implemented; under study for phased rollout.
China-Specific Tariffs	All Chinese imports (finished goods and raw ingredients) ([Exclusive: Trump tariff threats prompt some drugmakers to expedite shipments to US	**10%** (Feb 4, 2025) plus **another 10%** (Mar 4, 2025), *on top of* existing 7.5–25% from 2018–19 trade war	**Enacted:** 10% tariffs effective Feb 4; additional 10% from Mar 4. China retaliated with 10–15% counter-tariffs on U.S. goods.
Mexico & Canada Tariffs	Most imports from Mexico and Canada (broad goods; energy separate)	**25%** on general imports; **10%** on Canadian energy	**Enacted:** Effective Mar 4, 2025, in retaliation for migration & fentanyl issues. Some auto/USMCA parts exempt until April. Both countries announced counter-tariffs on U.S. exports.

Europe (EU) Tariff Threat	All imports from the European Union (esp. countries with trade surpluses, e.g. Germany, Ireland)	**25%** "reciprocal" tariff threatened	**Threatened:** Not yet in force as of Apr 2025. EU officials warned this approach is a "step in the wrong direction" and prepared counter-tariffs on U.S. goods.
Pharmaceutical Tariff	Imported **medicines and medical products** (finished drugs and key ingredients)	Trump has **repeatedly threatened 25%** reuters.com ; Pharma lobby pushing for <25% or gradual phase-in	**Under Review:** No specific pharma tariff implemented yet. Trump ordered a study on pharma tariffs. Industry expects tariffs are inevitable but seeks slower ramp to avoid immediate 25% shock.

As shown above, Trump's tariff policy is evolving rapidly.

A **10–20% blanket tariff on all imports** (often dubbed a "reciprocal" or universal tariff) was a signature 2024 campaign idea (Read at Piie). Early 2025 saw this vision begin to materialize: China was hit with new 10% duties (on **top** of existing tariffs), and **Mexico/Canada now face 25%** on most exports to the U.S.. By March 2025, Trump signaled an upcoming *"massive tariff plan"* to be unveiled on a so-called "Liberation Day," intended to cover *all nations* and address various trade imbalances. European officials have expressed alarm, especially as Trump explicitly called out **Ireland** for its role in hosting U.S. pharma companies (contributing to U.S. trade deficits). Notably, pharmaceuticals and medical devices – largely spared in prior trade wars – are **no longer off-limits** in Trump's rhetoric. In fact, Trump stated he will **"soon declare tariffs on the pharma industry,"** reversing past exemptions. The **25% tariff threat on pharmaceutical imports** looms, though industry lobbying may slow its implementation or reduce the initial rate.

Countries and Products in the Crosshairs

The new tariffs have both **geographic targets** and **product targets** that are relevant to aesthetic injectables:

- **European Union (especially Ireland):** Europe is a major pharmaceutical exporter to the U.S., with ~€90 billion in medicines shipped in 2023. Ireland, in particular, is crucial: it hosts large plants for Allergan/AbbVie (Botox) and other pharma giants. Trump's team has floated a 25% tariff on **all EU imports**, which would clearly encompass drugs made in Ireland. Trump criticized Ireland's tax breaks for pharma companies as contributing to U.S. deficits, suggesting Irish-made products could be targeted if no exemptions are carved out.

- **United Kingdom:** Although no specific UK-only tariff has been announced, a universal tariff or broad "allies" tariff would include the UK. The UK is home to Ipsen's Wrexham facility, which produces **Dysport** (abobotulinumtoxinA) for global distribution. Post-Brexit, the UK is outside the EU and would not be shielded if Trump's tariffs hit "all imports." Dysport and other UK-made medical products could thus face the same import duties at the U.S. border.

- **China and India:** While **Botox itself is not made in China or India**, these countries supply many **raw ingredients** and **generic drugs**. Trump's tariffs on China already include **finished drugs and raw pharmaceutical ingredients**. Though botulinum toxin products rely less on Chinese APIs (since they are biologics made in specialized facilities), any ancillary components or alternative aesthetic products (e.g. some dermal fillers or device components) sourced from China would cost more. India, another drug supplier, could also be impacted if broad pharma tariffs extend to all foreign API sources (though India-specific measures haven't been detailed in 2025 reporting).

- **North American Neighbors:** Mexico and Canada are not known manufacturing hubs for the botulinum toxins used in U.S. medspas. However, broader tariffs on these countries (25% as of March 2025) could indirectly affect medical device parts, packaging materials, or other supplies a medspa uses if sourced from across the border. (For example, if a medspa's equipment or needles are imported from Mexico or Canada, those items now carry higher costs.)

- **South Korea:** South Korea is relevant because **Jeuveau** (prabotulinumtoxinA-xvfs, a Botox competitor marketed by Evolus) is manufactured by Daewoong in South Korea. If Trump's tariff plan truly covers *all* imports, South Korean-made aesthetic injectables would also incur the import duty. There is no specific tariff rate announced for South Korea, but under a universal tariff scenario, Jeuveau would likely face the baseline import tax (e.g. 10%).

Which **products** specifically fall under these tariffs? Trump's broad approach implies **finished pharmaceuticals**, **active pharmaceutical ingredients (APIs)**, and even **medical devices** could all be affected unless exempted. Industry insiders note that **AbbVie's Botox, Merck's Keytruda,** and other top-selling drugs produced in Europe are squarely at risk if transatlantic tariffs proceed. Botox is explicitly cited as an example of a medicine made abroad that the U.S. relies on. Until now, medications were kept out of trade fights "due to likely patient harm". Going forward, however, neither the **Botox finished product** nor its **key ingredients** seem to have guaranteed protection from tariffs. Trump's inclusion of **"finished drugs and raw ingredients"** from China in tariff lists sets a precedent that could be applied to other regions.

To clarify how aesthetic injectables might be hit, **Table 2** lists major neuromodulator products used in medspas and their countries of origin. This illustrates which ones would be subject to import tariffs under Trump's policies:

Table 2. Major Aesthetic Injectables and Tariff Exposure by Origin

Product (Manufacturer)	Manufacturing Origin	Import Tariff Exposure
Botox® (AbbVie/Allergan)	Westport, **Ireland** (EU)	**Yes.** Ireland is in the EU; U.S. imports of Botox would face any tariff on European goods (proposed 25% threat). No exemption currently in place for pharma.
Dysport® (Ipsen/Galderma)	Wrexham, **U.K.**(and packaged in EU)	**Yes.** Subject to a universal tariff on all imports. The UK is not exempt (post-Brexit). A broad pharma tariff or global tariff (10–25%) would apply to Dysport vials imported from Britain.
Xeomin® (Merz Pharma)	**Germany** (EU) (Merz HQ in Frankfurt)	**Yes.** Made in Germany; would fall under any Europe-focused tariffs. Absent a special carve-out, Xeomin (incobotulinumtoxinA) shipments to the U.S. could face ~25% duty if EU tariffs are imposed.
Jeuveau® (Evolus/Daewoong)	**South Korea** (Jeuveau) (Daewoong's facility)	**Yes.** Subject to a general import tariff. South Korea is a U.S. ally but not excluded from Trump's proposed "all nations" tariff plan. A 10–20% tariff on all imports would likely encompass Jeuveau.
Daxxify® (Revance Therapeutics)	**United States** (California) (Daxxify)	**No.** Daxxify is manufactured domestically ("the only US-made frown line toxin" (Daxxify)). No import required, so it *avoids* import tariffs. (However, its competitors' price increases might affect market dynamics.)

As seen above, **Botox and its direct competitors (Dysport, Xeomin, Jeuveau)** are all produced overseas – primarily in Europe and Asia – meaning they fall within the ambit of Trump's import tariffs. The only major wrinkle relaxer made in the U.S. is **Daxxify**, which would not incur import duties. Notably, **Allergan's Irish facility** produces the entire global supply of Botox, so any tariff on imports from Ireland/Europe **directly hits Botox** costs in the U.S. Similarly, **Ipsen's UK plant** supplies all Dysport (Expansion of Ipsen), so Dysport is fully exposed to import taxes. In short, unless the administration grants an exemption for medical/aesthetic products, **Botox and similar injectables are directly included** in the new tariff regime as imported goods. There is **no indication of a carve-out** so far – on the contrary, pharma appears to be on Trump's target list now.

Indirect impacts could also arise. Even if somehow finished cosmetic injectables were exempted at the last minute, tariffs on **ingredients or components** could bite. For instance, Allergan might import certain raw materials, equipment, or packaging for Botox from other countries; those could become more expensive. However, given Botox's specialized production (a tightly controlled biologic process), the **primary concern is the tariff on the finished vials** entering the U.S.

Impact on Pricing and Medspa Cost Structure

If these tariffs take effect, the **cost structure for aesthetic injectables will shift upward.** A tariff is essentially a tax on imported goods. In practice, the importer (often the pharmaceutical company's U.S. subsidiary or distributor) pays the tariff at customs, and this cost is typically passed down the supply chain. Several likely outcomes for pricing:

- **Manufacturer Price Increases:** AbbVie (Allergan) and others may raise the wholesale price of their injectables to offset the tariff. For example, if a 10% tariff is imposed on Botox, the company faces a 10% higher cost to bring it in. Given Botox's strong demand, AbbVie is likely to **pass most of that cost to providers** rather than absorb it. Bloomberg analysts noted that AbbVie would either *"raise prices for its wildly popular drug, or eat the costs,"* and it's unlikely to absorb all of it. In fact, Allergan had already informed practices of a price increase effective early 2024 (prior to any official tariff) (Allergan Instagram Post), suggesting that either routine annual hikes or anticipation of higher costs was at play.

- **Higher Unit Costs for Medspas:** Medspas purchase Botox (and similar products) by the vial or unit. With tariffs, the **unit cost** will rise. Even a 10% duty is significant in this low-margin, high-volume product. For instance, if a vial of 100 units of Botox costs a medspa around $600 (hypothetically $6.00 per unit) pre-tariff, a 10% tariff could raise that to about $660 (or $6.60/unit). A 25% tariff would push it to $750 ($7.50/unit). Medspas will see their cost of goods for neurotoxin treatments spike accordingly. **Providers almost certainly will adjust their pricing to patients upward** to maintain margins. Indeed, many clinics announced about a $0.50 increase per unit in early 2024, citing Allergan's pricing changes. Future tariff-driven increases could be of similar or greater magnitude.

- **Patient Pricing and Demand:** Patients will ultimately pay more for their treatments. If a typical Botox session was $300, it might rise to $330 with a 10% import tax passed through, or closer to $375 with a 25% tariff. These higher prices might slightly dampen demand, especially for price-sensitive clients. However, **aesthetic treatments often have inelastic demand** among certain consumer segments; clients may accept moderate price hikes given the lack of perfect substitutes for Botox's effects. Still, medspas should be prepared for some patients to **shop around or try alternatives** if prices jump noticeably.

- **Competitive Dynamics:** One interesting scenario is that a U.S.-made product (*Daxxify*) might become relatively more competitive on price if imports face tariffs. Revance Therapeutics could choose to **hold Daxxify's price steady**, effectively undercutting Botox once Botox's price includes tariffs. (That said, Daxxify is a newer product and has its own premium pricing strategy due to longer duration; whether they adjust prices remains to be seen.) Other competitors like **Jeuveau or Dysport** would likely match any Botox price increase since they face the same tariff costs. In essence, tariffs could cause an *industry-wide price inflation* for neurotoxin treatments, with all brands moving upward in tandem.

- **Medicare/Insurance Costs:** (For completeness, note that Botox is also used medically for conditions like migraine, spasticity, etc., covered by insurance.) The U.S. government and insurers could see higher expenses if drug tariffs apply, as pointed out by industry analysts. While cosmetic use is out-of-pocket for patients, any general drug price increases can spill over into healthcare costs broadly. Medspa owners should be aware of this context, as it may influence public sentiment and regulatory responses to price hikes.

In summary, **Botox and similar products would become more expensive to obtain and administer**. The size of the increase corresponds to the tariff rate imposed (10%, 20%, 25%, etc.). Pharma companies have warned that tariffs will "increase drug costs and create access barriers for patients" – essentially, higher prices might put treatments out of reach for some. For a medspa, the direct effect is a higher cost per vial, which will either compress profit margins or necessitate charging clients more. Most likely, medspas will raise prices to keep their business sustainable.

Potential Supply Chain Disruptions and Availability

Beyond pricing, tariffs introduce **friction into the supply chain** for aesthetic injectables. Several potential disruptions to anticipate:

- **Rush to Stockpile:** In late 2024 and early 2025, as Trump's tariff threats gained credibility, some pharmaceutical companies began **expediting shipments and stockpiling inventory** in the U.S. to get ahead of the tariffs . Reuters reports that drugmakers shipped extra product by air freight from Europe in anticipation of tariff implementation. This suggests that suppliers of Botox/Dysport/Xeomin likely built up some reserves in U.S. warehouses. Medspa owners might have seen unusually robust availability in early 2025 (and possibly special promotions to draw down inventory before year-end). However, once tariffs kick in, that **surge of supply could be followed by a dip** if companies temporarily pause shipments to avoid high fees or to renegotiate logistics.

- **Transit Delays and Logistical Challenges:** Tariffs can slow down customs clearance if new documentation or processing is required for taxed goods. If many goods are being hit by tariffs at once (on a "Liberation Day" tariff rollout, for example), ports and customs brokers might face **backlogs**. Also, if companies shift from sea freight to **air freight** (as noted by DHL's observation of rising pharma air cargo, capacity constraints or higher costs could lead to sporadic delays. Air freight is faster but expensive; not all shipments can be economically airlifted. For products like Botox which require cold chain handling, any change in transport mode must be carefully managed. So far, no specific shortages of Botox have been reported, but the **logistics strategy is under pressure** – companies are incurring higher shipping costs to ensure continuous supply.

- **Risk of Shortages:** Pharma industry groups have cautioned that abruptly slapping 25% tariffs on medicines could **lead to drug shortages** in the U.S.. The reasoning is that supply chains cannot be relocated or ramped up domestically overnight, and some foreign suppliers might not absorb the cost – potentially scaling back shipments if they become unprofitable. In the aesthetic injectables market, Allergan/AbbVie and others are highly unlikely to *stop* supplying Botox to the U.S. (it's too lucrative a market), but smaller players might struggle. For example, if Evolus has thin margins on Jeuveau, a tariff might hurt its ability to compete unless it raises capital or increases prices. Any missteps (like failing to secure enough tariff-compliant inventory) could result in **temporary stock-outs** of a product. Medspas should be prepared with alternatives in case one brand is intermittently unavailable.

- **Interconnected Global Supply Chains:** The U.S.-EU medicine supply chain is deeply interwoven – certain components or drugs go back and forth. Industry experts emphasize that "interrupting these flows will hurt patient access" and is a *"lose-lose situation"* for both sides. In a full-blown tariff standoff, we can't rule out retaliatory moves by the EU that, while not likely to target medicines (for moral/political reasons), could indirectly affect regulatory cooperation or shipping efficiency. The pharmaceutical industry is lobbying hard in both Washington and Brussels to **exclude medical goods from the tariff war**. If they succeed, availability might remain stable; if they fail, medspas could see **tighter supplies and longer lead times** for orders, at least in the initial phase of the tariffs.

- **Domestic Production Timeline:** One theoretical way to avoid import disruptions is to make the products in the U.S. Trump's goal is to spur domestic manufacturing of drugs so the U.S. "does not have to rely on other countries". However, for complex biologics like Botox, building U.S. production is a **long-term prospect**. PhRMA (the industry group) notes it takes *5–10 years and around $2 billion* to set up a new pharmaceutical manufacturing facility that meets regulatory standards. In fact, some companies (Novo Nordisk, Eli Lilly, etc.) have announced big investments in U.S. plants, but those are for other drugs and won't alleviate the short-term Botox supply issue. Thus, in the next few years, U.S. medspas remain dependent on imports from Ireland, UK, etc. Any significant tariff-induced disruption in those supply lines could not be quickly mitigated by domestic production.

In summary, **supply is expected to continue but with potential bumps**. Manufacturers are taking steps (like stockpiling and shipping early) to prevent a crisis if tariffs hit. Medspa owners should nonetheless keep an eye on their product order fulfillment times. It would be prudent to maintain a slightly larger inventory on hand than usual, if possible, to buffer against any short-term delays. So far, the tariff talk has not caused major shortages – a testament to contingency planning by the industry – but the situation remains fluid.

Strategic Recommendations for Medspa Owners

Given the above landscape, medspa owners and administrators should be proactive in responding to tariff-related changes. Here are strategic steps to consider:

1. Inventory Management: Pre-purchase and stock up on key injectables before new tariffs take effect (if a specific date is announced for a tariff hike). As drug companies themselves have done, having extra inventory can save cost (buy at pre-tariff prices) and ensure you can continue treating patients during any supply hiccups. Be mindful of product shelf-life and storage requirements, but Botox and others have a reasonable shelf life when refrigerated unopened. Don’t hoard irresponsibly, but a cushion of a few months’ supply is wise if tariffs loom.

2. Diversify Product Offerings: Consider **offering multiple brands** of botulinum toxin. If you currently rely on Botox exclusively, establish accounts to also purchase Dysport, Xeomin, or Jeuveau. This way, if one brand experiences a shortage or sharp price hike, you have alternatives. Also evaluate **Daxxify**, the U.S.-made toxin that is not subject to import costs. While Daxxify may have a higher sticker price now, its long duration could appeal to some patients, and its U.S. production insulates it from trade volatility. Having a broader arsenal gives flexibility to switch based on availability and cost.

3. Update Pricing Strategies: It’s important to **revisit your pricing model** in light of increased costs. You might implement a **small incremental price increase** per unit for injectable treatments (e.g., a few dollars more per unit), rather than a drastic jump, to test patient acceptance. Communicate that an increase is due to manufacturer cost changes (which are in turn driven by tariffs). Some practices might introduce tiered pricing or **membership programs**: for example, selling packages or subscriptions that lock in a rate for patients who commit to regular treatments. This can help secure cash flow and patient loyalty even as prices shift. Use cost-analysis to ensure your profit margin per treatment remains healthy after accounting for the higher product cost.

4. Patient Communication: Transparent communication with patients is crucial. Many clients may have heard about tariffs in the news in a general sense; explaining how “a new import tax on medical products” has increased the cost of Botox is a factual way to justify a price increase. Craft a message (via email newsletter, social media, or in-clinic signage) that: a) Reassures patients you have supply and will continue to offer their favorite treatments; b) Explains that due to government trade policy, your cost for the product went up by X%, necessitating a price adjustment; and c) Emphasizes your commitment to quality and safety (e.g., you won’t resort to grey-market or unapproved sources to cut costs – an important point in aesthetics where counterfeit product dangers exist). Educating patients preemptively can make them more understanding of the situation.

5. Cost Efficiency and Scheduling: With higher per-unit costs, it's even more important to **avoid waste**. Train staff to draw up and reconstitute injectables efficiently to use every drop from each vial. Optimize scheduling to batch patients in a way that maximizes vial usage (since once reconstituted, Botox must be used within a certain time). Also keep an eye on overhead – if product costs rise, look for small savings elsewhere in the practice to avoid simply passing all costs to patients. This could include negotiating better deals on other supplies or tightening appointment no-show policies (to prevent wasted product draws).

6. Advocacy and Information Gathering: Stay connected with professional organizations (like the American Med Spa Association or dermatology/cosmetic surgeon societies) which often provide updates on regulatory changes. They may also coordinate **advocacy efforts** urging the government to exempt medical/aesthetic products from tariffs. Adding your voice – or at least staying informed – can help in the long run. Also monitor news from Allergan/AbbVie and other vendors; they may announce plans or programs to help practices through tariff-related cost increases (for instance, temporary rebates, bulk purchase discounts, or loyalty point incentives through programs like Allergan's Alle). **Leverage any supplier support programs** to mitigate the impact on your practice.

7. Contingency Planning: Develop a simple contingency plan for worst-case scenarios (e.g., a sudden 25% tariff overnight, or a temporary import ban in a trade dispute). Identify what you would do if Botox supply was cut for 1–2 months – do you have enough alternate product? Could you prioritize certain high-need patients? Having a game plan ensures you're not scrambling if something changes quickly. It may also be wise to set aside a small **financial reserve** from your profits now to cushion against potential dips in profitability if costs spike or patient volume momentarily drops.

By implementing these strategies, medspa owners can better navigate the uncertainties introduced by tariff policies. The key is to **be proactive rather than reactive**: adjust your purchasing and pricing ahead of time, communicate openly, and remain flexible in sourcing. While tariffs on aesthetic injectables pose challenges, with careful planning a medspa can continue to thrive and provide quality care to clients.

Conclusion

Donald Trump's trade tariffs – from a blanket import tax to targeted country tariffs – represent a significant external factor that could reshape the economics of aesthetic medicine. The **proposed tariffs (10–25% or more)** on imports from places like Ireland, the EU at large, and Asia mean that **Botox and its competitors are likely to become more expensive** in the U.S. market. Without exemptions, these levies act as a tax on beauty: medspas and patients will shoulder higher costs for the same treatments. Moreover, the complex international supply chains for products like Botox introduce risks of **supply disruption**, although manufacturers are taking steps to maintain consistent supply.

Medspa owners should view this as a call to action to **shore up their business practices** – from inventory and pricing to patient relations. By anticipating changes (e.g. stocking up before a tariff hits, adjusting prices in stages, and offering alternatives), practices can cushion the impact. The situation also highlights the value of innovation, such as U.S.-based manufacturing for critical products, which in the long run could reduce exposure to geopolitical trade winds.

In the immediate term, all eyes are on policy developments: both industry lobbyists and allied governments are working to **exclude medical and pharmaceutical goods from the crossfire of tariffs**. The outcome of those discussions will directly influence whether aesthetic injectables see a price surge or not. For now, prudence dictates that medspas plan for some level of impact. With thoughtful strategy, clinics can continue to deliver confidence-boosting treatments to patients – even as the cost of doing business adjusts to a new trade reality.

Sources:

- Reuters News – *Trump tariff announcements and pharma industry responses* (Exclusive: Pharma industry lobbies Trump for phased tariffs, sources say | Reuters) (Exclusive: Trump tariff threats prompt some drugmakers to expedite shipments to US | Reuters)
- U.S. and UK Government Releases – *Trade and manufacturing background (Allergan in Ireland; Ipsen in UK)* (Welsh Secretary announces multi-million pound expansion of Ipsen's Wrexham site - GOV.UK)
- Industry Analysis – *Pharmaceutical trade war impact on prices and supply* (Exclusive: Trump tariff threats prompt some drugmakers to expedite shipments to US | Reuters)
- Company Statements – *Product origins and pricing notices* (The DAXXIFY® Difference - Long-lasting Frown Line Treatment) (Jeuveau – UNAPOLOGETICALLY YOU, FEWER FROWN ... - Evolus)